Story · Medicine & Biotech

Zydus' Saroglitazar Shows Promising Phase 2b Results in MASH Patients

1 outlet · first reported by Medical Dialogues 3d ago

Coverage, in order

  1. 3d ago
    Medical Dialogues India obscure
    Zydus' Saroglitazar Shows Promising Phase 2b Results in MASH Patients

    New Delhi: Zydus Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Limited, has announced positive results from a Phase 2b clinical trial evaluating saroglitazar magnesium in adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.